Sarasota-based Lakewood-Amedex Inc., a biopharmaceutical firm developing anti-infective products, recently appointed current board member Dr. Steve Miley as its Chief Medical Officer (CMO) and Steven Kates as Chief Scientific Officer and VP for regulatory affairs.
"These experienced executives bring to Lakewood-Amedex important capabilities essential to us as our first human clinical trial is now underway and in the strategic planning of our next two INDs (investigational new drug applications) which we hope to file with the FDA as soon as possible," Steve Parkinson, president and CEO, said.
With years of emergency medicine and clinical trial experience, Miley previously founded and served at family practices and urgent care centers. He holds a medical degree from the University of South Florida’s College of Medicine and has been affiliated with many hospitals and specialty practices in Florida.
Bringing more than 25 years of pharmaceutical and R&D expertise, Kates has developed several life science products over his career, held previous senior positions at numerous companies and written and co-authored many articles, reviews and patents. Kates earned his BS in chemistry from Bates College, Ph.D. in Synthetic Organic Chemistry from Brandeis University and conducted post-doctoral studies at The Massachusetts Institute of Technology.
Lakewood-Amedex specializes in next-generation solutions to serious infectious diseases.
Want to get notified whenever we write about Lakewood-Amedex, Inc ?
Sign-up Next time we write about Lakewood-Amedex, Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.